Adam Feuerstein from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Ouster of FDA’s Peter Marks alarms a biopharma industry that saw him as an ally - 25 days ago STAT+: Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment - 6 months ago STAT+: Perplexing results from Duchenne muscular dystrophy trial raise questions about gene therapies - 6 months ago
2	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Ouster of FDA’s Peter Marks alarms a biopharma industry that saw him as an ally - 25 days ago STAT+: Corbus reports first Western data for closely tracked ADC cancer drug - 2 months ago STAT+: Biotech is in a dark place - 2 months ago Crisis in CRISPR world, RFK Jr.’s promises, and a novel non-opioid pain drug - 3 months ago Remembering a remarkable Duchenne champion - 3 months ago STAT+: Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance - 3 months ago STAT+: With a major patent cliff coming, will JPM play host to some serious deal-making? - 4 months ago STAT+: Worst Biopharma CEO of 2024? It’s no contest - 4 months ago The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 4 months ago STAT+: Investors in Padlock Therapeutics sue Bristol Myers Squibb over ‘milestone’ payments - 4 months ago STAT+: Biotech companies detail emerging efforts to ease ‘conditioning’ before genetic treatments - 5 months ago Biopharma leaders lay out vision for the future of blood cancer treatment - 5 months ago Sanofi advances a drug for a rare, platelet-destroying disease - 5 months ago Roche’s TIGIT troubles continue, a novel Alzheimer’s target misses the mark, and other biotech news - 5 months ago Pfizer’s new R&D head, a VC deep-dive, and a new FDA commissioner? - 5 months ago STAT+: The state of biotech M&A 2024 - 5 months ago STAT+: Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit - 6 months ago STAT+: Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment - 6 months ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 6 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 6 months ago STAT+: Study on Sarepta Therapeutics’ Duchenne therapy diverges from the company line - 6 months ago STAT+: Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores - 6 months ago STAT+: Perplexing results from Duchenne muscular dystrophy trial raise questions about gene therapies - 6 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 6 months ago STAT+: Pharmalittle: We’re reading about an Italian acquisition, Medicare Advantage market growth, and more - 7 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 7 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 7 months ago STAT+: Can iTeos and GSK solve TIGIT’s troubles? - 7 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 8 months ago STAT+: Alnylam versus BridgeBio: The ATTR-CM debate - 8 months ago STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal - 8 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 8 months ago STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more - 8 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 8 months ago Listen: Drug pricing drops & psychedelics under fire - 8 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 9 months ago STAT+: On Andrew Left and the government’s fraud case - 9 months ago STAT+: Sage suffers pipeline setback with failure of drug to treat essential tremor - 9 months ago STAT+: With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer’s disease world - 9 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 10 months ago STAT+: Roche’s TIGIT study was a bust. What’s the outlook for its next big bet? - 10 months ago A biotech’s binary bet ends badly - 10 months ago STAT+: Pharmalittle: We’re watching more positive data for Ozempic, a Lilly factory expansion, and more - 11 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 11 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 12 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - about 1 year ago STAT+: The inside story of Enhertu’s pan-tumor approval - about 1 year ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - about 1 year ago STAT+: Weed for weight loss, and more from Biotech Land - about 1 year ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - about 1 year ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	Crisis in CRISPR world, RFK Jr.’s promises, and a novel non-opioid pain drug - 3 months ago The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 4 months ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 6 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 6 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 6 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 7 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 7 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 8 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 8 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 8 months ago Listen: Drug pricing drops & psychedelics under fire - 8 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 9 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 10 months ago
4	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: With a major patent cliff coming, will JPM play host to some serious deal-making? - 4 months ago The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 4 months ago Pfizer’s new R&D head, a VC deep-dive, and a new FDA commissioner? - 5 months ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 6 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 6 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 6 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 7 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 7 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 8 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 8 months ago Listen: Drug pricing drops & psychedelics under fire - 8 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 9 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 10 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 11 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 12 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - about 1 year ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - about 1 year ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - about 1 year ago
5	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Biopharma leaders lay out vision for the future of blood cancer treatment - 5 months ago
6	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	Biopharma leaders lay out vision for the future of blood cancer treatment - 5 months ago
7	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	Biopharma leaders lay out vision for the future of blood cancer treatment - 5 months ago Sanofi advances a drug for a rare, platelet-destroying disease - 5 months ago
8	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 8 months ago
9	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - about 1 year ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - about 1 year ago